Cesca Therapeutics Announces the Launch of its PXP™ System for Automated Processing of Bone Marrow Cells
July 16 2018 - 8:30AM
Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a
market leader in automated cell processing and point-of-care,
autologous cell-based therapies, today announced that its device
subsidiary, ThermoGenesis®, has launched its PXP System for the
rapid processing of autologous bone marrow cells in the
point-of-care setting, such as surgical centers or clinics.
“The commercial launch of our novel PXP System
is significant, as it addresses many of the shortcomings of
currently-available systems, most notably, red blood cell
contamination in the resulting cell concentrate that is thought to
diminish the efficacy of cell based treatments,” said Chris Xu,
PhD, chief executive officer of Cesca Therapeutics. “PXP allows
clinicians to rapidly achieve very high stem and progenitor cell
recovery rates with negligible RBC contamination – typically less
than 2% of the starting sample. The on-time commercial launch of
PXP serves to further solidify our position as a leading innovator
in the field of cellular processing, and together with our
CAR-TXpress™ and related X-Series™ systems, comprises what we
believe is the most advanced and clinically differentiated
portfolio of cellular processing solutions available today.”
The ThermoGenesis PXP System is an automated,
closed system that harvests a precise volume of cell concentrate
from a sample of bone marrow aspirate. PXP can generate a
concentration of bone marrow in less than 20 minutes, with
consistently high mononuclear cell (MNC) and CD34+ progenitor cell
recovery rates and greater than 98% depletion of contaminating
RBCs. Processing data is captured using ThermoGenesis’ proprietary
DataTrak™ software to assist with Good Manufacturing Practice (GMP)
process monitoring and reporting information.
For more information, please visit:
www.thermogenesis.com.
About Cesca Therapeutics
Inc. Cesca
Therapeutics Inc. (the “Company”) develops, commercializes and
markets a range of automated technologies for CAR-T and other
cell-based therapies. Its device division, ThermoGenesis Corp.,
provides a full suite of solutions for automated clinical
biobanking, point-of-care applications, and automation for
immuno-oncology. The Company is developing an automated,
functionally-closed CAR-TXpress™ platform to streamline the
manufacturing process for the emerging CAR-T immunotherapy
market.
Company Contact:Cesca Therapeutics Inc.Wendy
Samford916-858-5191ir@cescatherapeutics.com
Investor Contact:Rx CommunicationsPaula
Schwartz917-322-2216pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Sep 2023 to Sep 2024